Summary
The binding of non-steroidal antirheumatic drug piroxicam to human serum albumin, human plasma and serum has been studied by equilibrium dialysis at 22°C, pH 7.4. The binding data were analyzed according to Scatchard model. The values of binding parameters obtained for human serum albumin are quite similar to those obtained for human plasma and serum (N 1=0.3, K 1=3.0· 105 l/mol; N 2=7, K 2=3.5 · 103 l/mol). We suggest that piroxicam interacts with the albumin fraction in human plasma proteins.
The displacement of piroxicam (in the therapeutical concentration of 4.5 · 105 mol/l) from the binding to human serum albumin and human plasma has been studied. The concentration of albumin and albumin fraction in plasma was 2.9·10−4 mol/l. The displacement substances were drugs — diazepam, warfarin and salicylic acid, and endogenous substances-bilirubin and palmitic acid. Only in the presence of salicylic acid in high clinical concentration (14.5·10−4 mol/l) and palmitic acid in the molar ratio to albumin 5:1, free piroxicam substantially increased, which may be of clinical significance. Other studied substances displaced piroxicam only in high concentrations exceeding the therapeutical and physiological range.
The evidence was found for the similarity of piroxicam and warfarin high-affinity binding site.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aarons LI, Schary WL, Rowland M (1979) A in vitro study of drug displacement interactions: warfarin-salicylate and warfarin-phenylbutazone J Pharm Pharmacol 31:322–330
Chakrabarti SK (1978) Cooperativity of warfarin binding with human serum albumin induced by free fatty anion. Biochem Pharmacol 27:739–743
McElnay JC, D'Arcy PF (1983) Protein binding displacement interactions and their clinical importance. Drugs 25:495–513
Fehske KJ, Müller WE, Wollert U (1981) The localization of drug binding sites in human serum albumin. Biochem Pharmacol 30:678–692
Goodman DS (1958) The interaction of human serum albumin with long-chain fatty acid anions. J Am Chem Soc 80:3892–3898
Hobbs DC (1983) Pharmacokinetics of piroxicam in man. Eur J Rheum Inflam 6:46–55
Hobbs DC, Twomey TM (1979) Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. J Clin Pharmacol 19:270–281
Hultmark D, Borg KO, Elofsson R, Palmer L (1975) Interaction between salicylic acid and indomethacin in binding to human serum albumin. Acta Pharm Suec 12:259–276
Ishizaki T, Nomura T, Abe T (1979) Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. J Pharmacokin Biopharmacol 7:369–381
Jacobsen J (1969) Binding of bilirubin to human serum albumin. —Determination of the dissociation constants. Fed Eur Biochem Soc Lett 5:112–114
Klotz IM, Hunston DL (1979) Protein affinities for small molecules: Conceptions and misconceptions. Arch Biochem Biophys 193:314–328
Krach-Hansen U (1981) Molecular aspects of ligand binding to serum albumin. Pharmacol Rewievs 33:17–53
Levy G (1979) Pharmacokinetics of salicylate in man. Drug Metabolism Rewievs 9:3–19
Metzler CM, Elfring GL, McEwen AJ (1974) A user manual for NONLIN and associated programs. The Upjohn Co., Kalamazoo
Novák M (1965) Colorimetric ultramicro method for the determination of free fatty acids. J Lipid Res 6:431–433
Rendić S, Alebić-Kolbah T, Kajfež F (1981) Binding of piroxicam to human serum albumin. Acta Pharm Jugoslavica 31:215–220
Ridd MJ, Brown KF, Moore RG, Nation RL (1982) Drug plasma binding and non-esterified fatty acids: methodologic considerations. Internat J Pharmaceutics 11:11–20
Rosenthal HE (1967) A graphic method for the determination and presentation of binding parameters in a complex system. Anal Biochem 20:525–532
Rudman D, Bixler TJ, Del Rio AE (1971) Effect of free fatty acids on binding of drugs by bovine serum albumin, by human serum albumin and by rabit serum. J Pharmacol Exp Therap 176:261–272
Scatchard G (1949) The attraction of protein for small molecules and ions. Ann NY Acad Sci 51:660–672
Schiantarelli P, Acerbi D, Bovis G (1981) Some pharmacokinetics properties and bioavailability by oral and rectal route of piroxicam in rodent and in man. Arzneim Forsch drug Res 31:92–97
Sjöholm I, Ekman B, Kober A, Ljungstedt-Pählman I, Seiving B, Sjödin T (1979) Binding of drugs to human serum albumin: XI Mol Pharmacol 16:767–777
Solomon HM; Schrogie JJ, Williams D (1968) The displacement of phenylbutazone-14C and warfarin-1/2 ÷C from human albumin by various drugs and fatty acids. Biochem Pharmacol 17:143–151
Tillement JP, Zini R, D'Athis P, Vassent G (1974) Binding of certain acidic drugs to human albumin: Theoretical and practical estimation of fundamental parameters. Eur J Clin Pharmacol 7:307–313
Tillement JP, Lhoste F, Giudicelli JF (1978) Diseases and drug protein binding. Clin Pharmacokin 3:144–154
Tsutsumi E, Inaba T, Mahon WA, Kalow W (1974) The displacing effect of a fatty acid on the binding of diazepam to human serum albumin. Biochem Pharmacol 24:1361–1362
Udenfried S (1962) Fluorescence assay in biology and medicine. Academic Press, New York London p 244
Vesel ES, Passanati T, Johnson AO (1975) Failure of indomethacin and warfarin to interact in normal human volunteers. J Clin Pharmacol 15:486–495
Wilkinson GR (1983) Plasma and tissue binding considerations in drug disposition. Drug metabolism rewievs 14:427–465
Wilting J, Thart BJ, De Gier JJ (1980) The role of albumin conformation in the binding of diazepam to human serum albumin. Biochim Biophys Acta 626:291–298
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Trnavská, Z., Trnavský, K. Plasma protein binding and interaction studies with piroxicam. Naunyn-Schmiedeberg's Arch. Pharmacol. 327, 81–85 (1984). https://doi.org/10.1007/BF00504996
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00504996